AJ8 Stock Chart & Stats
€5.90
€0.60(11.32%)
At close: 4:00 PM EDT
€5.90
€0.60(11.32%)
Day’s Range― - ―
52-Week Range€2.30 - €7.05
Previous CloseN/A
Volume38.00
Average Volume (3M)200.00
Market Cap
€311.79M
Enterprise Value€391.15
Total Cash (Recent Filing)€18.74M
Total Debt (Recent Filing)€40.71M
Price to Earnings (P/E)3.0
Beta1.60
Next Earnings
Nov 10, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.72
Shares Outstanding45,020,410
10 Day Avg. Volume283
30 Day Avg. Volume200
Financial Highlights & Ratios
PEG Ratio9.24
Price to Book (P/B)-0.34
Price to Sales (P/S)0.82
P/FCF Ratio-0.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€16.69Price Target Upside182.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.77
Revenue Forecast (FY)€118.56M
Bulls Say, Bears Say
Bulls Say
Revenue And Profitability ReboundThe sharp TTM improvement shows that partnered programs and licensing activity can generate substantial revenue and earnings. If repeatable, this improves the company’s ability to fund development, although consistency remains important.
Focused Phase 3 Development StrategyConcentrating resources on a defined high-risk colon cancer population may improve capital allocation and execution. Positive Phase 2 results provide clinical support, while Phase 3 progress could materially strengthen Agenus’s pipeline.
Improved Debt Position And Funding RunwayThe substantial debt reduction lowers near-term repayment pressure, while new financing provides more time to advance clinical programs. This runway can reduce execution risk over the next several quarters, despite remaining funding needs.
Bears Say
Persistent Cash BurnA large ongoing cash deficit means Agenus cannot yet fund operations internally and may need additional capital. Continued investment in clinical trials could keep cash use elevated, increasing financing dependence and execution risk.
Negative Shareholder EquityNegative equity reflects accumulated losses and leaves the company with a thin capital base. It limits financial flexibility and increases sensitivity to refinancing terms, equity issuance, and any setbacks affecting future funding access.
Dilutive And Expensive Financing DependenceUsing equity to satisfy debt costs and relying on high-interest borrowing can dilute shareholders and increase future financial obligations. This structure highlights the challenge of funding development while cash generation remains negative.
Agenus News
AJ8 FAQ
What was Agenus’s price range in the past 12 months?
Agenus lowest stock price was €2.30 and its highest was €7.05 in the past 12 months.
What is Agenus’s market cap?
Agenus’s market cap is €311.79M.
When is Agenus’s upcoming earnings report date?
Agenus’s upcoming earnings report date is Nov 10, 2026 which is in 78 days.
How were Agenus’s earnings last quarter?
Agenus released its earnings results on Aug 06, 2026. The company reported -€0.009 earnings per share for the quarter, missing the consensus estimate of €0.039 by -€0.048.
Is Agenus overvalued?
According to Wall Street analysts Agenus’s price is currently Undervalued.
Does Agenus pay dividends?
Agenus does not currently pay dividends.
What is Agenus’s EPS estimate?
Agenus’s EPS estimate is >-0.01.
How many shares outstanding does Agenus have?
Agenus has 45,020,410 shares outstanding.
What happened to Agenus’s price movement after its last earnings report?
Agenus reported an EPS of -€0.009 in its last earnings report, missing expectations of €0.039. Following the earnings report the stock price went down -7.092%.
Which hedge fund is a major shareholder of Agenus?
Currently, no hedge funds are holding shares in DE:AJ8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agenus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€16.69 (182.93% Upside)
€16.69 (182.93% Upside)
Blogger Sentiment
Bullish
DE:AJ8 Sentiment 67%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.85%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.76%
Trailing 12-Months
Company Description
Agenus
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.
AJ8 Stock 12 Month Forecast
Average Price Target
€16.69
▲(182.93% Upside)
Technical Analysis
Inovio Pharmaceuticals
―
Oncolytics Biotech
―
―
TuHURA Biosciences
―
Spero Therapeutics
―
Instil Bio
―